Form 4: Emergent BioSolutions Director Trades RSUs and Options

Emergent BioSolutions Director Keith Katkin reports transactions involving restricted stock units and stock options, including the acquisition of RSUs and the sale of shares to cover tax obligations.

Summary

• Director Keith Katkin acquired 25,344 restricted stock units (RSUs) on April 30, 2026, as an annual grant for board and committee service.
• These RSUs are expected to vest one year from the grant date, provided Katkin remains a director.
• Katkin also sold 15,481 shares of common stock on April 30, 2026, at a weighted average price of $8.28 per share.
• The sale of shares was executed under a Rule 10b5-1 trading plan to satisfy tax obligations related to RSU vesting.
• Additionally, Katkin was granted 11,296 stock options with an exercise price of $7.99, also for board and committee service, vesting on the same terms as the RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it details routine equity grants and a pre-planned sale for tax purposes, without indicating significant shifts in the director's conviction or the company's prospects.

Positives

• Acquisition of 25,344 RSUs indicates continued equity incentive for director service.
• Grant of 11,296 stock options further aligns director interests with the company's performance.
• Sale of shares under a Rule 10b5-1 plan demonstrates proactive tax planning and adherence to trading policies.

Negatives

• Sale of 15,481 shares could be interpreted as a reduction in direct beneficial ownership, although explained by tax obligations.

Risks

• Vesting of RSUs and stock options is contingent on the Reporting Person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
• The sale of shares, even under a 10b5-1 plan, may be perceived negatively by the market if not clearly understood as a tax-related event.

Future Outlook

The vesting of restricted stock units and stock options is subject to the reporting person remaining a director through the respective vesting dates.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for directors and officers to report changes in their beneficial ownership of company stock, reflecting common compensation and trading practices within the biotechnology and pharmaceutical sectors.

Stakeholder Impact

• Shareholders: The sale of shares, though for tax reasons, reduces the director's direct holdings, which could be a minor point of observation.

Next Steps

• Vesting of RSUs and stock options on the Annual Grant Vesting Date, subject to continued directorship.

Key Dates

Keywords

Form 4, Emergent BioSolutions, Keith Katkin, Director, RSU, Stock Options, Beneficial Ownership, Rule 10b5-1, SEC Filing, Insider Trading